Current Report Filing (8-k)
September 28 2020 - 6:45AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934.
Date
of Report: September 28, 2020
(Date
of earliest event reported)
Oragenics,
Inc.
(Exact
name of registrant as specified in its charter)
FL
|
|
001-32188
|
|
59-3410522
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
Number)
|
4902
Eisenhower Boulevard, Suite 125
Tampa,
FL
|
|
33634
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
813-286-7900
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock
|
|
OGEN
|
|
NYSE
American
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01 Other Events.
On
September 28, 2020, Oragenics, Inc. (the “Company”) announced that the Company received a response from Biomedical
Advanced Research and Development Authority (“BARDA”) indicating that BARDA determined not to enter into negotiations
with the Company, at this time, for the proposal concerning the development of the Company’s SARS-CoV-2 Vaccine, Terra CoV-2.
The Company intends to continue to seek funding through other sources, including but not limited to, contracts and grants from
various federal government agencies.
A
copy of the press release announcing these events is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
by reference herein.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
In
accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized on this 28th day of September, 2020.
|
ORAGENICS, INC.
(Registrant)
|
|
|
|
BY:
|
/s/
Michael Sullivan
|
|
|
Michael
Sullivan
Chief
Financial Officer
|
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
From May 2023 to May 2024